Longer-term data from the SELECT trial followed 17,604 adults for four years. Semaglutide maintained a mean weight loss of 10.2% over 208 weeks, while the placebo group lost only 1.5%[1]. That sustained result matters because many weight-loss interventions lose effectiveness over time. A meta-analysis pooling six trials and nearly 4,000 participants confirmed a mean reduction of 11.8% body weight and 12.2 kg of absolute loss compared to placebo[6].

Real-world results line up with the clinical data. A multicentered study of 304 patients found 13.4% weight loss at 12 months in routine clinical practice, with patients without type 2 diabetes achieving even higher losses of 16.9%[RWE].

Semaglutide vs Tirzepatide: How They Compare

One of the biggest questions in weight management right now is how semaglutide measures up against tirzepatide (Mounjaro/Zepbound), a newer dual GIP/GLP-1 receptor agonist.

Head-to-head trial results comparing semaglutide and tirzepatide over 72 weeks.

The SURMOUNT-5 trial gave us a direct answer. In this head-to-head study of 751 adults with obesity, tirzepatide produced 20.2% weight loss compared to 13.7% with semaglutide over 72 weeks[7]. Tirzepatide also led to a greater reduction in waist circumference: 18.4 cm versus 13.0 cm[7].

Both medications caused similar rates of gastrointestinal side effects, mostly mild to moderate during the dose-escalation phase[7]. Semaglutide has the advantage of more long-term safety data and an oral formulation. Tirzepatide currently delivers higher weight loss on average. Your provider can help you weigh these differences based on your health profile.

Side Effects: What You Need to Know

Digestive side effects are the most common concern with semaglutide. Being honest about the numbers helps you prepare.

Most semaglutide side effects are digestive and tend to ease as your body adjusts.

According to a meta-analysis of six trials, gastrointestinal events occur about 1.5 times more often on semaglutide than on placebo[6]. Here is what that looks like in practice:

• Nausea: The most frequently reported side effect, with odds roughly four times higher than placebo. It typically peaks during dose increases and fades over weeks[6].
• Vomiting: Also about four times more likely than placebo. Usually mild to moderate and tied to the early treatment period[6].
• Diarrhea: Roughly twice as common as placebo. Tends to be manageable for most people[6].
• Constipation: About 2.4 times more likely than placebo. Staying hydrated and eating enough fiber can help[6].

The good news: only 4.5% of participants in the STEP 1 trial stopped treatment because of gastrointestinal side effects, compared to 0.8% on placebo[2]. Serious adverse events were not significantly increased overall[6]. The gradual dose-escalation schedule — starting low and increasing over 16 to 20 weeks — is designed to minimize these effects.

Benefits Beyond Weight Loss

Some of the most compelling semaglutide research has nothing to do with the scale. The SELECT trial revealed that semaglutide reduced major cardiovascular events by 20% in people with obesity and existing heart disease[3].

Semaglutide has shown cardiovascular and metabolic benefits that go beyond weight reduction.

A 2025 meta-analysis quantified these cardiovascular benefits further. Across over 24,000 participants, semaglutide was associated with a 76% reduction in heart failure hospitalizations, a 21% reduction in all-cause mortality, and a 24% reduction in nonfatal heart attacks[8]. These are striking numbers, and researchers believe the benefits may extend beyond what weight loss alone would explain[3][8].

Additional metabolic improvements have been documented across trials. Blood pressure, glucose levels, C-reactive protein (a marker of inflammation), and lipid profiles all improved significantly in semaglutide groups[6]. For a deeper understanding of how GLP-1 medications produce these effects, read our explainer on how GLP-1 agonists work.

Practical Guide: Injectable vs Oral and How to Choose

You now have two ways to take semaglutide for weight loss: a weekly injection or a daily pill. The oral formulation reached a major milestone with clinical trial results matching the injectable version.

Semaglutide is available as a weekly injection or a daily oral tablet.

In the OASIS 1 trial, oral semaglutide at 50 mg daily produced 15.1% weight loss at 68 weeks — nearly identical to the injectable 2.4 mg dose[4]. A lower oral dose of 25 mg daily achieved 13.6% weight loss at 64 weeks[5]. Both oral doses showed higher rates of gastrointestinal events (74-80%) compared to placebo (42-46%), though most were mild to moderate[4][5].

Here is a practical breakdown to discuss with your healthcare provider:

• Weekly injection (2.4 mg): Starts at 0.25 mg and escalates over about 16 weeks. Best studied over long durations, including four-year cardiovascular data[1][2].
• Daily oral tablet (25-50 mg): No injection required. Must be taken on an empty stomach with a small sip of water, then wait 30 minutes before eating[4][5].
• Timeline for results: Most trials show maximum weight loss between 48 and 72 weeks. This is not a quick fix.
• Lifestyle still matters: Every major trial combined medication with a reduced-calorie diet and increased physical activity.
• Medication interactions: Semaglutide slows gastric emptying, which may affect how your body absorbs other oral medications. This is especially important if you take drugs with a narrow therapeutic window[4].

Frequently Asked Questions

Q. How much weight can you realistically lose on semaglutide?

Clinical trials show an average loss of 10-15% of body weight over one to two years[1][2][6]. In real-world practice, patients without diabetes averaged 16.9% loss at 12 months[RWE]. Individual results depend on your starting weight, adherence, diet, and activity level.

Q. Is oral semaglutide as effective as the injection?

Yes, clinical data suggests they are comparable. Oral semaglutide at 50 mg daily achieved 15.1% weight loss at 68 weeks, on par with the 14.9% from injectable 2.4 mg in the STEP 1 trial[2][4]. The oral version must be taken on an empty stomach with specific timing.

Q. What is the difference between semaglutide and tirzepatide?

Semaglutide targets the GLP-1 receptor alone, while tirzepatide targets both GLP-1 and GIP receptors. In a head-to-head trial, tirzepatide achieved 20.2% weight loss compared to 13.7% for semaglutide over 72 weeks[7]. Semaglutide has more long-term safety data and an available oral formulation.

Q. Do you regain weight after stopping semaglutide?

The SELECT trial showed sustained weight loss of 10.2% over four years of continued use[1]. Current evidence suggests that weight regain is common after discontinuation, which is why ongoing treatment and lifestyle changes are both important topics to discuss with your provider.

Q. Does semaglutide help your heart, not just your weight?

Yes. The SELECT trial demonstrated a 20% reduction in major cardiovascular events[3]. A meta-analysis found a 21% reduction in all-cause mortality and a 76% reduction in heart failure hospitalizations among people with overweight or obesity[8].

References

[1] Ryan DH et al., "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial," Nature Medicine, 2024. DOI: 10.1038/s41591-024-02996-7

[2] Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183

[3] Lincoff AM et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2307563

[4] Knop FK et al., "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1)," The Lancet, 2023. DOI: 10.1016/S0140-6736(23)01185-6

[5] Wharton S et al., "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity," New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2500969

[6] Qin W et al., "Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes," Diabetes, Obesity and Metabolism, 2024. DOI: 10.1111/dom.15386

[7] Aronne LJ et al., "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity," New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2416394

[8] Cleto AS et al., "Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity," International Journal of Obesity, 2025. DOI: 10.1038/s41366-024-01646-9

[RWE] Ghusn W et al., "Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study," International Journal of Obesity, 2024. DOI: 10.1038/s41366-023-01456-5

This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.